My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Gemcitabine And Cisplatin

gemcitabine and cisplatin

Gemcitabine and cisplatin (GC)

Find out what GC (gemcitabine and cisplatin) chemotherapy is, how you have it and other important information about having GC. GC is a combination of chemotherapy drugs and is also known as Gemcis or Gemcisplat.

  • gemcitabine (or Gemzar)
  • cisplatin

How does gemcitabine + cisplatin work?

Each of the medications in the gemcitabine and cisplatin (also known as gem/cis) regimen are designed to kill or slow growth of bladder cancer cells. Cisplatin plus gemcitabine is given to shrink bladder tumors and decrease symptoms from bladder cancer. It can be given either after surgery to eliminate microscopic cells, or it can be given before surgery to shrink the size of the bladder tumor and minimize the size of the surgery. If there is no metastatic disease (cancer is limited to bladder only and not other parts of the body), cisplatin plus gemcitabine are commonly given with the goal of cure.

How you have it

You have the treatment through a drip into your arm. A nurse puts a small tube (a cannula) into one of your veins and connects the drip to it. You might need a central line. This is a long plastic tube that gives the drugs into a large vein, either in your chest or through a vein in your arm. It stays in while you’re having treatment, which may be for a few months.

Side effects of gemcitabine and cisplatin (GC)

Find out about the side effects of the cancer drug combination gemcitabine and cisplatin (GC). Tell your doctor or nurse if you have any side effects so they can help you manage them. Your nurse will give you a contact number to ring if you have any questions or problems. If in doubt, call them.

New Drugs in Combined-Modality Treatment

The 1995 meta-analysis showed that chemotherapy improves survival when added to radiotherapy for patients with unresectable stage III non-small-cell lung cancer. These data have been recently confirmed by two consecutive prospective trials from the Cancer and Leukemia Group B (CALGB) and Radiation Therapy Oncology Group (RTOG), both reporting a survival advantage in favor of sequential chemoradiotherapy vs radiotherapy alone.[18,19] Concurrent cisplatin-based chemoradiotherapy vs sequential radiotherapy alone has also been evaluated in phase.

Conclusions

The new gemcitabine/cisplatin regimen has been extensively evaluated in advanced non-small-cell lung cancer in phase II and phase III randomized trials with a response rate ranging between 21% and 40% and a median survival of approximately 9 months. These data place this combination among the most active regimens in non-small-cell lung cancer and suggest the importance of a thorough evaluation in more favorable disease stages.

Discussion

These disappointing results may be due to our schedule with the CDDP repeated early in the treatment course (eighth day). Sheperd et al. in fact reported that a GEM and CDDP schedule may influence activity in advanced non-small-cell lung cancer, with the weekly schedule obtaining the worst results. The administration of CDDP after a loading dose of GEM (second day) or later in the treatment course (fifteenth day) seemed to be associated with the most favorable therapeutic index. However, in spite of the used schedules, the trials investigating this combination in pancreatic cancer gave overall conflicting results since the present study and the study of Heinemann et al.

Know More About This Medicine and Buy Now : MedyPharma.com

Loading...